We continue to increase our reach and access in India, say Sun Pharma execs

Senior Sun Pharma executives speak on a two-pronged strategy for the China market, beginning R&D of biosimilar products, and more

After posting a 43 per cent rise in Q1 profit after tax (PAT) and 29 per cent jump in sales of specialty products, Sun Pharma is now eyeing to commercialise its specialty products basket in countries outside the US. Speaking to Sohini Das, Sun Pharmaceutical Industries chief financial officer (CFO) C S Muralidharan and chief executive officer (CEO), India business, Kirti Ganorkar, talk about future plans and the incremental innovation in products that they plan to bring to India. Edited excerpts: 

Some of your specialty products like Ilumya and Absorica are now likely to face competition. How are you planning